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Abstract 
Neuroendocrine tumours of the lung represent a distinct subgroup of primary lung neoplasms, 
characterized by particular morphologic, ultrastructural, immunohistochemical and molecular 
peculiarities and different biological behavior. A detailed pathological diagnosis including 
immunohistochemistry, Ki-67, mitotic rate and necrosis status can be helpful to identify the 
different subtypes. The optimal management of advanced well-differentiated lung neuroendocrine 
tumors is still debated and can be very challenging for the clinician. Currently, no established 
therapeutic algorithm exists for patients with unresectable or metastatic typical carcinoids and 
atypical carcinoids. To highlight the importance of a multidisciplinary management we report the 
case of a patient affected by unresectable lung neuroendocrine tumors, who has benefited from 
integration strategy, resulting in complete surgical excision of the tumour. 
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Introduction  
 Neuroendocrine tumors (NETs) arise from neuroendocrine cells in various anatomic sites, most 
commonly the gastrointestinal and pulmonary systems. Bronchopulmonary or lung NETs 
represent approximately 25% of primary lung neoplasms and 20%–25% of primary NETs (1). 
In the 2015 World Health Organization classification, lung NETs form a cluster of diseases that 
can be subdivided into prognostic subtypes with possible implications for choice of therapy (2).  
Over the years, several reports have commented on the risk of overinterpreting lower respiratory 
tract carcinoid tumors, either typical or atypical as small-cell carcinomas in small biopsy tissue 
fragments or cytologic samples (3). 
A detailed pathological diagnosis including immunohistochemistry, Ki-67, mitotic rate and 
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necrosis status can be helpful to identify the different subtypes. 
Successful treatment of lung NETs relies on accurate and timely diagnosis. 
The optimal management of advanced well-differentiated lung NETs is still debated, due to their 
relative rarity and the lack of prospective randomized studies. Therefore, the management of 
advanced lung NETs should be discussed by a multidisciplinary team (4).  
Currently, no established systemic treatments exist for patients with unresectable or metastatic 
typical carcinoids and atypical carcinoids. 
Therapeutic options for advanced pulmonary carcinoids include chemotherapy, Somatostatin 
(SST) analogs (SSAs), Interferon, Everolimus, or the new option of Peptide Receptor 
Radionuclide Therapy (PRRT) (5).  
To highlight the importance of a stepwise multidisciplinary approach to effectively manage the 
disease, we present the case of an unresectable pulmonary NET, treated with integration 
modality, resulting in a complete surgical excision. 
 
Case Report 
In December 2014, a 49 years old male patient, current smoker, with family history of SCLC 
(small cell lung cancer) in good clinical conditions (Performance status ECOG 0), referred to our 
hospital suffering from cough and fever. The radiological work-up with a contrast-enhanced 
computed tomography (CT) scan had revealed complete atelectasis of the upper lobe of left lung, 
with a solid lesion of 7 x 4 cm determining obstruction of segmental bronchus for the superior 
lobe, with mediastinal lymph node involvement. The bronchoscopy had evidenced an infiltrative-
growing mass that obstructed the left upper lobe.  
The pathology report, performed in a small peripheral hospital, was consistent with a poor 
differentiated carcinoma of the lung with neuroendocrine features (NSE+; Cromogranin+; CD 
56+).  
No further pathological data were available. A pathological revision in our hospital was 
suggested but patient refused the option. 
The disease staging was completed with a fluorodeoxyglucose (18FDG) Positron Emission 
Tomography (PET) scan, that confirmed a clinical stage cT2bN3M0 (Stage IIIB-TNM 7th 
Edition) with a Standardized Uptake Value (SUV) max in left mass of 4.3. The extension of the 
disease and the high volume to irradiate increased risk of severe toxicities from concomitant 
radiotherapy and chemotherapy. Consequently, in January 2015 he started sequential a program 
of chemo-radiotherapy with three courses of Cisplatin-Etoposide at standard doses. After the 
conclusion of chemotherapy tumor re-staging with contrast-enhanced CT demonstrated a stable 
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Fig.1 Clinical course 
177Lu-Dotatoc PRRT was continued up to 6 courses, with good tolerance and no relevant adverse 
events. The CT/68Ga-PET restaging after PRRT treatment documented a significant reduction of  
tumor extension (47 x 29 mm) compared with baseline, with partial atelectasis of upper lobe of 
the left lung and no pathological lymph nodes, with a with substantial stability of SUV max 
values in the primary tumor, compared with August 2015. 
Based on the favorable response with 177Lu-Dotatoc PRRT, imaging restaging, age, good clinical 
conditions, tumor histology and disease staging, the case was revaluated by the multidisciplinary 
team and in October 2016 the patient underwent a left pneumonectomy. 
The pathology report showed a complete pathologic response to 177Lu-Dotatoc PRRT, with no 
evidence of active disease in the resected lung. A standard follow up program was started. 
 
Discussion 
With the term lung NETs, in the 2015 WHO classification are included a series of different histo-
pathological entities, including: SCLC and combined SCLC; Large cell neuroendocrine 
carcinoma (LCNEC) and combined LCNEC; and Carcinoid tumors, consisting of Typical 
Carcinoid (TC) and Atypical Carcinoid (AC) tumors. Pulmonary carcinoids (PCs) represent 
~30% of all well-differentiated NETs throughout the body, whereas LCNEC and SCLC accounts 
for ~90% of all poor-differentiated neuroendocrine carcinomas (1,2,5,6,). The implementation of 
the WHO classification in daily practice can be difficult due to: infrequent exposure in general 
pathology practice; recognized inter-observer variation, even among experienced pathologists; 
the requirement of surgical resected tissue for assessment of all morphological criteria, making 
diagnosis based on small biopsy and cytological specimens tenuous; the difference between the 
pulmonary, thyroid, and gastrointestinal classification system for NETs with regard to advised 
nomenclature and mitosis/Ki67 evaluation (7).  
Ki-67 index is a useful diagnostic marker for neuroendocrine tumors. The role of Ki-67 is mainly 
to separate the high-grade neuroendocrine tumours from the carcinoids. 
Conflicting results have been reported in separating typical from atypical carcinoid tumors (2). 
Consequently is not recommended in this setting (8). 
Somatostatin receptor imaging may be useful to determine the disease burden in such patients.  
Whenever available, the use 68Ga-DOTATE PET should be preferred to SRS (Somatostatin 
receptor scintigraphy) for the study of patients with low/intermediate grade NETs (5). 68Ga-
DOTATE PET may be used not only for disease staging, but also to evaluate patients suitable for 
Peptide Receptor Radionuclide Therapy (PRRT). 
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The optimal management of advanced well-differentiated lung NETs is still debated, due to their 
relative rarity and the lack of prospective randomized studies and their management should be 
discussed by a multidisciplinary team (4). Therapeutic options for advanced pulmonary 
carcinoids include Somatostatin (SST) analogs (SSAs), Interferon, Everolimus, chemotherapy or 
Peptide Receptor Radionuclide Therapy (PRRT) (5). 
 
Conclusions and Future Perspectives 
The present case underlines the importance of a detailed pathological diagnosis of lung NETs to 
identify the histotype and define therapeutic strategy, suggesting that second-opinion may be 
useful in selected cases, especially in small biopsies.  
A multidisciplinary management of lung NETs represent the best approach to personalize 
treatment and obtain the better results.  
PRRT with 177Lutetium is an intriguing therapeutic strategy for low/intermediated grade SSTR-
expressing lung NETs and could be an option as neoadjuvant therapy in patients with 
unresectable pulmonary carcinoids. 
The therapeutic landscape of lung NETs is rapidly evolving and the promising results of recent 
clinical trials RADIANT-4 and LUNA (9,10) have supported the introduction of Everolimus, a 
new therapeutic option in advanced/metastatic setting. 
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